Standard BioTools Offloads Mass Cytometry Unit, Secures $30M Illumina Buyout to Clear Path for Treeline Merger
LAB is trading near its 52-week low of $0.703 (14% above the low).
Summary
Standard BioTools sold its Mass Cytometry business for up to $10 million in a seller's note and received $30 million from Illumina to terminate earnout and royalty obligations, both aimed at simplifying the company ahead of its merger with Treeline Biosciences.
Key Events · M&A and Partnerships · LAB
-
Mass Cytometry Business Sold
The Mass Cytometry business was sold to Multiplex Bio for up to $10 million, structured as a seller's note and a potential milestone payment. At closing, Standard BioTools will also provide a $10 million working capital loan to the buyer, making the transaction cash-neutral upfront.
-
Illumina Buyout of Contingent Payments
Illumina paid $30 million to terminate the 2026 earnout and all future royalty obligations from its prior acquisition of Standard BioTools' SomaLogic business, adding cash to the pro forma balance sheet for the Treeline merger.
-
HSR Clearance for Treeline Merger
On July 21, 2026, the FTC granted early termination of the Hart-Scott-Rodino waiting period, removing a key regulatory condition for the pending reverse merger with Treeline Biosciences.
-
Merger Timeline and Conditions
Both the Mass Cytometry sale and the Treeline merger are expected to close by the end of 2026, subject to Standard BioTools stockholder approval and other customary conditions.
Analysis · LAB · Life Sciences
To clear the decks for its reverse merger with Treeline Biosciences, Standard BioTools is executing a pair of transactions that reshape its balance sheet and portfolio. The Mass Cytometry business was sold to Multiplex Bio for up to $10 million, structured as a seller's note and a milestone payment, while the company simultaneously extends a $10 million working capital loan to the buyer — rendering the divestiture cash-neutral at closing and effectively shedding a non-core asset. In a separate move, Illumina paid $30 million to extinguish all remaining earnout and royalty obligations tied to the earlier SomaLogic sale, injecting cash into the pro forma balance sheet that will enhance Standard BioTools' valuation in the Treeline exchange ratio. Adding to the momentum, the FTC granted early HSR clearance, removing a regulatory obstacle. These steps streamline the company ahead of the merger, though the Mass Cytometry sale terms — no upfront cash, a seller's note, and a loan back to the buyer — hint at limited buyer appetite and a pragmatic focus on simply getting the deal done.
At the time of this filing, LAB was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $303.2M. The 52-week trading range was $0.70 to $1.72. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.